1. Introduction {#sec1-geriatrics-02-00026}
===============

Stroke is a leading cause of death and disability worldwide with an annual incidence of 152,000 per year in the UK \[[@B1-geriatrics-02-00026]\] and 795,000 in the United States \[[@B2-geriatrics-02-00026]\]. The cost of providing acute and long-term care, along with estimated loss of productivity costs in stroke patients, is over 8 billion pounds per year \[[@B3-geriatrics-02-00026]\] in the UK. Annual costs in the United States reach 33.6 billion dollars, of which 7.6 billion dollars are attributed directly to inpatient stays \[[@B2-geriatrics-02-00026]\] representing a major economic burden to the health services.

Length of stay (LOS) in acute medical care is a significant contributor to the financial implication of caring for stroke patients and the ability to accurately predict which patients are likely to require longer inpatient care would be desirable for both budgetary planning and healthcare provider considerations, and also in communicating with patients and families to manage expectations at a vulnerable and uncertain time \[[@B4-geriatrics-02-00026]\].

Total anterior circulation stroke (TACS), as defined by the Oxford Community Stroke Project classification \[[@B5-geriatrics-02-00026]\], constitutes around 17% of stroke \[[@B5-geriatrics-02-00026]\] and is a severe form of stroke associated with higher mortality rates \[[@B6-geriatrics-02-00026]\], higher healthcare costs \[[@B7-geriatrics-02-00026]\] and longer length of stay \[[@B8-geriatrics-02-00026]\] than other stroke subtypes. Deeper insight and better understanding of factors that determine LOS in TACS creates the potential for targeted intervention to reduce the associated health care burden.

We \[[@B9-geriatrics-02-00026],[@B10-geriatrics-02-00026]\] and others \[[@B11-geriatrics-02-00026]\] have derived and validated clinical prediction tools to predict length of stay in acute stroke, but mostly in cohorts of stroke patients with varying severity. We recently identified major determinants of mortality in TACS and derived a novel scoring system, the TACS-6 score, to predict mortality \[[@B12-geriatrics-02-00026]\]. However, there is no tool in current clinical use that has been derived to specifically predict length of stay following this most severe form of stroke. The purpose of this study was to identify what factors in TACS patients were associated with hospital length of stay.

2. Methods {#sec2-geriatrics-02-00026}
==========

The study participants were drawn from the Norfolk and Norwich Stroke and Transient Ischemic Attack (TIA) Prospective Register that has routinely collected data from its inception (Nov 1996) at the Norfolk and Norwich University Hospital. The patients included in the study were admitted between 1996 and 2012. The hospital is a regional tertiary care hospital with a catchment population of \~750,000, which provides a comprehensive stroke care service including a hyper acute stroke unit, a step-down acute stroke unit and multi-disciplinary medical and rehabilitation care. Data collection methods were previously reported \[[@B13-geriatrics-02-00026],[@B14-geriatrics-02-00026]\].

For the purposes of this study, patients diagnosed with a TACS and entered into the registry for the first time were included. TACS was defined as a significant ischemic or hemorrhagic event affecting the middle and/or anterior cerebral artery territories. Clinically, a diagnosis of TACS was made by the presence of all three of the following: unilateral weakness (and/or sensory impairment) of face, arm and leg, homonymous hemianopia and higher cortical dysfunction (dysphasia and/or visuospatial disorder). If lateralisation (i.e., unilateral weakness) was absent, the diagnosis was made radiologically, such as by arterial territory involved and degree of the neurological deficit in conjunction with other clinical signs (e.g., eye deviation/obvious neglect). Computed tomography (CT) was the first line imaging modality, with Magnetic Resonance Imaging (MRI) performed in CT negative cases. Not all ischaemic stroke underwent CT angiography in addition to non-contrast CT.

Variables of interest included age, sex, stroke sub-type (ischemic or hemorrhagic), pre-stroke functional status as a marker of frailty assessed using the pre-stroke modified Rankin score (mRs 0 = no symptoms, mRs 5 = severe disability, completely dependent on care) and pre-stroke residence. Patients with modified rankin scores 4 and 5 (moderately severe and severe disability) were combined for the analysis as these represented collectively a vulnerable group. We considered sheltered housing as a pre-care home state (*N* = 8) and mental health facility (*N* = 2) as a care setting. Comorbidities were retrieved from electronic discharge letters on the patient administration system. Comorbidities (including atrial fibrillation (AF), diabetes mellitus, myocardial infarction (MI), chronic kidney disease, and congestive heart failure) that could influence LOS were included. Comorbidities with less than 5 patients recorded were excluded from the analyses as comparisons with these groups would not be statistically useful. Length of stay was considered as the period in days from date of admission to date of discharge from the hospital for those who survived or from date of admission to date of death for those patients who died as an inpatient.

Descriptive statistics for each potential explanatory factor was given as the number and percentage in each category. A linear regression model was used to identify the association between potential explanatory factors and length of stay. When there was less than 5 events the category it was excluded from the model. The assumptions standard regression analysis was not met as the residuals were not normally distributed, hence a non-parametric bootstrap was used to estimate the p-values and confidence intervals. 1000 iterations of the bootstrap were used. Statistical significance was considered as *p* ≤ 0.05. Statistical analysis was performed using Stata 14 (StataCorp, College Station, TX, USA).

Ethical approval was obtained from the Newcastle and Tyneside National Health Service (NHS) Research Ethics Committee (12/NE/0170) and the study protocol was approved by the Steering Committee of the Register.

Given the inherent differences in management and prognosis, the analyses were conducted for ischemic and hemorrhagic stroke specifically in the whole sample. Subgroup analysis was then performed to examine the factors associated with length of stay separately for patients who survived to discharge and those who died as inpatients in line with our previous work \[[@B15-geriatrics-02-00026]\].

3. Results {#sec3-geriatrics-02-00026}
==========

A total of 2965 patients with total anterior circulation stroke (42.0% male, mean age 76.9 ± 10.8 years, 58.0% female, mean age 81.5 ± 9.3 years) were included in the current study. The median age of the whole sample was 81 years (range = 20--102 years; IQR 74--86 years). There were 232 (7.8%) aged less than 65 years, 1717 (57.9%) aged 65--84 years and 1016 (34.3%) aged 85 years or more. 2439 (82.2%) had an ischemic stroke. 526 (17.7%) had a haemorrhagic stroke. 2693 (90.8%) patients were admitted with clinical features consistent with lateralisation of neurological deficit. 456 (15.4%) patients were admitted from a care home. 1477 (58.7%) were fully independent prior to admission with baseline modified Rankin scores of 0. Data for modified Rankin scores was available for 2517 out of 2965 patients. 486 (16.4%) had atrial fibrillation, 290 (9.8%) had congestive heart failure, 54 (1.8%) had chronic kidney disease, 150 (5.1%) had a previous myocardial infarction and 88 (3%) were diabetic. 1707 patients (57.6%) died during their admission, of whom 1379 (46.5%) patients had an ischaemic TACS and 328 (11.1%) patients had a haemorrhagic TACS. [Table 1](#geriatrics-02-00026-t001){ref-type="table"} shows the sample characteristics.

[Table 2](#geriatrics-02-00026-t002){ref-type="table"} details the length of stay analysis separately for the ischemic and hemorrhagic stroke subtypes. In the ischemic stroke group, moderate (mean LOS 16 days, *p* = 0.014) and moderately severe or severe disability (mean LOS 15 days, *p* = 0.015) prior to TACS (modified Rankin score 3 and 4 or 5) were both significantly associated with shorter length of stay as compared with those who had no baseline disability (modified Rankin score 0). In the haemorrhagic stroke group, the presence of lateralisation (mean LOS 16 days, *p* = 0.004) was associated with a longer length of stay and those patients with a history of congestive heart failure (mean LOS 5 days, *p* = 0.027) had significantly shorter length of stay.

[Table 3](#geriatrics-02-00026-t003){ref-type="table"} and [Table 4](#geriatrics-02-00026-t004){ref-type="table"} show the stroke subtype specific length of stay results for the patients who were alive at discharge or who died as inpatients respectively. In patients who survived an ischemic TACS, those who lived in a care home prior to admission had significantly shorter length of stay (mean LOS 20 days, *p* = 0.013). In those who survived a bleed, patients with advanced age (mean LOS 33 days for patients aged ≥85 years, *p* = 0.006) had significantly longer LOS. In patients who died following an ischemic event, the presence of lateralisation (mean LOS 12 days, *p* = 0.003) was associated with increased length of stay. Amongst patients who died following a haemorrhagic TACS, the presence of lateralisation (mean LOS 10 days, *p* = 0.014), advanced age (mean LOS 11 days for patients aged ≥85 years, *p* = 0.04) and modified Rankin scores 1 (mean LOS 15 days, *p* = 0.042), 2 (mean LOS 19 days, *p* = 0.025) as compared with those who had a baseline score of 0 were associated with longer of lengths of stay.

4. Discussion {#sec4-geriatrics-02-00026}
=============

We have identified several factors associated with both shorter and longer length of stay in patients who presented with a total anterior circulation stroke. Predictive criteria such as the PLOS score \[[@B11-geriatrics-02-00026]\] includes variables such as stroke severity assessed by NIHSS score, stroke type, decreased consciousness on admission, congestive heart failure and atrial fibrillation to predict length of stay but its generalizability has been questioned \[[@B16-geriatrics-02-00026]\] and it was not specific to TACS patients, who often suffer the greatest burden of post-stroke disability and the most prolonged length of stay.

To date, much of the literature has focussed on stroke severity, rather than on specific clinical features of neurological deficit, as a predictor of length of stay, with increasing stroke severity scores associated with longer inpatient admission \[[@B17-geriatrics-02-00026],[@B18-geriatrics-02-00026]\]. However, lateralization forms part of the criteria of assessment in several validated stroke severity scoring tools, including the NIHSS score and the Canadian Neurological Score \[[@B19-geriatrics-02-00026],[@B20-geriatrics-02-00026],[@B21-geriatrics-02-00026]\]. Early functional improvement in paretic limbs following anterior circulation stroke has been shown to predict greater recovery while those limbs lacking voluntary movement in the few days following the occurrence of stroke were associated with poorer outcome \[[@B22-geriatrics-02-00026]\]. Our study had similar findings with lateralisation increasing length of stay in those patients who died of ischaemic or haemorrhagic TACS and increasing overall inpatient stay in haemorrhagic TACS, with such a deficit likely reflecting increased severity of stroke and vulnerability to complications of immobility, including infection, venous thrombo-embolism and pressure sores. Severity scoring tools were not included in the analysis for the current study. Rather, the inclusion of a broader binary measure of impairment (lateralization or not) instead of the specific grade of limb weakness may have decreased the potential for inter-rater variability in the assessment of neurological deficit.

Advancing age has previously been shown to be predictive of longer length of stay \[[@B23-geriatrics-02-00026]\] and poor outcomes in stroke, including change in residence to nursing home care reflecting an individual's increased dependence and care needs if they survived the stroke \[[@B24-geriatrics-02-00026]\]. In clinical practice the delayed availability of such care often represents a rate-limiting aspect to speed of discharge in health care systems such as in the National Health Service in the UK. The current finding of advanced age being associated with increased length of stay is supported by a recently validated length of stay prediction tool \[[@B10-geriatrics-02-00026]\] with a similar cohort mean age being observed in both studies, and differs to earlier studies which had younger cohorts that did not show an association between age and length of stay \[[@B18-geriatrics-02-00026]\]. An ever-increasing elderly population is a prominent factor in contemporary medical practice that places further demands on health services. Recognising the impact age has on length of stay has therefore important resource allocation implications, emphasising the requirement for early review of patient's pre & post-morbid functional status, detailed collateral history at the point of admission and a multi-disciplinary (including social worker) review given the higher likelihood that an elderly patient will need greater resource (i.e., care or change in residency to nursing home) utilisation. The earlier thus work could be done for these elderly patients the more efficiently their LOS could be influenced. Equally, stroke services should take into account patient demographics such as age, not just the number of population they serve, so stroke unit beds are able to cope with increasing ageing populations.

Congestive heart failure (CHF) has previously been reported to prolong length of stay following stroke \[[@B11-geriatrics-02-00026],[@B25-geriatrics-02-00026]\] and transient ischaemic attack \[[@B26-geriatrics-02-00026]\], forming one of the criteria in the aforementioned PLOS score. In keeping with prolonged length of stay CHF has been reported as a predictor of increased cost following stroke \[[@B25-geriatrics-02-00026],[@B27-geriatrics-02-00026]\]. It could be expected that increased comorbidity prior to TACS would contribute to more prolonged recovery, placing further limitation on rehabilitation effort and exacerbating vulnerability to complications that accompanies an acute insult such as a TACS. However, in the current study patients with a haemorrhagic stroke and a history of CHF had approximately only one third of the mean length of stay of those patients who were without pre-morbid cardiac impairment. CHF has also been associated with increased mortality following stroke \[[@B28-geriatrics-02-00026]\] and this may also account for the decreased length of stay in the haemorrhagic TACS cohort in the current study, where patients with poor physiological reserve succumbed having suffered the most severe form cerebrovascular injury. It would be of interest to observe similar findings in future studies to establish this link further. Cardiac failure and cerebrovascular disease share similar risk factors, such as hypertension, atrial fibrillation and hypercholesterolaemia (as a contributor to ischaemic cardiomyopathy). The association of poor outcomes between heart failure and stroke underlines the importance of risk factor modification and achieving primary and secondary prevention targets.

Higher pre-stroke modified Rankin scores have previously been reported to influence length of stay and mortality \[[@B29-geriatrics-02-00026]\]. In the primary analysis a reduced length of stay was seen in patients with higher disability (mRs group 3 and 4 or 5) who suffered an ischaemic TACS. This may in part be due to higher inpatient mortality rates being seen in the study's cohort who had a pre-stroke mRs of 3 (*p* = 0.003) and 4 (*p* = 0.014) and an associated relatively shorter LOS. Equally, among those who survived to discharge, patients who had higher degrees of disability may have been less likely to benefit from intensive, acute stroke rehabilitation prompting more timely discharge back to their pre-stroke residence with appropriate care arrangements that were already catering for their needs. This is also reflected by the fact patients admitted from care settings had shorter LOS. Amongst those patients who died, minimal to mild pre-morbid disability predicted increased length of stay following a haemorrhagic event. This longer length of stay likely reflects that these patients were now significantly unwell following their event but may have had some degree of physiological reserve that enabled them to survive for a period of time before succumbing to their acute illness. Equally, discharge planning may have been a factor with these patients becoming more care dependent following such an event and their prolonged stay reflecting the time requirement to arrange new, suitable discharge destinations such as a high intensity nursing home or hospice.

The main study limitation is that it is based on one centre's experience in the UK NHS setting and patient cohort where stroke management resources, delivery and patient characteristics may differ in other places and settings. Also, the analysis was conducted retrospectively. However, the data were collected prospectively, except for co-morbidities, which were documented prospectively in the medical notes and identified at a later stage using electronic records. This prospective data collection of consecutive admissions and the lack of exclusion criteria to the register limit the possibility of selection bias and reflect a real world picture.

5. Conclusions {#sec5-geriatrics-02-00026}
==============

In summary, the identification of contributors to length of stay would aid the development of useful prediction criteria in future studies. This study with a large cohort of patients contributes valuable information to predicting which patients will have an extended or likely shorter inpatient stay following a TACS. This information can potentially be used for planning of services and projections of future health care costs in stroke populations with knowledge about the incidence of TACS within local stroke patient populations. Further studies in multiple settings would be beneficial to validate predictive criteria for TACS length of stay given its wide-ranging impact on healthcare providers and patients.
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###### 

Total anterior circulation stroke patient cohort characteristics.

                       Total   \%     Ischemic   \%     Hemorrhagic   \%
  -------------------- ------- ------ ---------- ------ ------------- -------
  **Stroke Type**                                                     
  Ischaemic            2439    82.3   \-                \-            
  Haemorrhage          526     17.7   \-                \-            
  **Mortality**                                                       
  Survived             1258    42.4   1060       43.5   198           37.6
  Died                 1707    57.6   1379       56.5   328           62.4
  **Age**                                                             
  \<65 years           232     7.8    167        6.9    65            12.3
  65--85 years         1717    57.9   1381       56.6   336           63.9
  ≥85 years            1016    34.3   891        36.5   125           23.8
  **Gender**                                                          
  Female               1719    58.0   1452       59.5   267           50.8
  Male                 1246    42.0   987        40.5   259           49.2
  **Lateralization**                                                  
  Yes                  2693    90.8   2256       92.5   437           83.1
  No                   272     9.2    183        7.5    89            16.9
  **Residence**                                                       
  Care Home            456     15.4   399        16.3   57            10.8
  Home Alone           988     33.3   829        34.0   159           30.2
  Home Family          1521    51.3   1211       49.7   310           59.0
  **Rankin Score**                                                    
  mRs ^1^ 0            1477    58.7   1175       56.8   302           67.46
  mRs 1                206     8.2    175        8.4    31            6.9
  mRs 2                235     9.3    193        9.3    42            9.4
  mRs 3                312     12.4   264        12.8   48            10.7
  mRs 4 or 5           287     11.4   262        12.7   25            5.6
  **Comorbidity**                                                     
  AF ^2^ No            2479    83.6   1965       80.6   514           97.7
  AF Yes               486     16.4   474        19.4   12            2.3
  CHF ^3^ No           2675    90.2   2155       88.4   520           98.9
  CHF Yes              290     9.8    284        11.6   6             1.1
  CKD ^4^ No           2911    98.2   2385       97.8   526           100
  CKD Yes              54      1.8    54         2.2    0             0
  MI ^5^ No            2815    94.9   2312       94.8   503           95.6
  MI Yes               150     5.1    127        5.2    23            4.4
  DM ^6^ No            2877    97.0   2352       96.4   525           99.8
  DM Yes               88      3.0    87         3.6    1             0.2

^1^ mRs = modified Rankin scale; ^2^ AF = atrial fibrillation; ^3^ CHF = congestive heart failure; ^4^ CKD = chronic kidney disease; ^5^ MI = myocardial infarction; ^6^ DM = diabetes mellitus.
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###### 

Adjusted combined length of stay analysis with 95% confidence intervals of ischaemic and haemorrhagic TACS.

                       Ischaemic TACS   Haemorrhagic TACS                                                                   
  -------------------- ---------------- ------------------- ------ ------------- ------- ----- ------ ------ -------------- -------
  **Age**                                                                                                                   
  \<65 years           167              19.7                23.5                         65    13.8   17.9                  
  65--84 years         1381             17.8                17.7   −5.87--2.08   0.350   336   15.1   17.4   −5.98--4.17    0.727
  ≥85 years            891              16.9                18.1   −6.64--1.92   0.280   125   16.2   18.9   −5.42--6.88    0.816
  **Gender**                                                                                                                
  Female               1452             17.7                18.3                         267   15.2   17.6                  
  Male                 987              17.6                18.3   −2.34--1.15   0.506   259   15.1   18.1   −2.07--4.81    0.436
  **Lateralisation**                                                                                                        
  No                   183              15.2                21.1                         89    9.7    18.3                  
  Yes                  2256             17.8                18     −2.07--5.01   0.415   437   16.3   17.5   2.32--11.9     0.004
  **Residence**                                                                                                             
  Home Alone           829              18.5                20                           159   16.2   19.2                  
  Home Family          1211             17.9                18.1   −3.05--0.88   0.280   310   15     17.2   −5.67--2.81    0.509
  Care home            399              15.1                14.5   −4.77--0.74   0.152   57    13.4   17.3   −9.74--4.03    0.416
  **Rankin Score**                                                                                                          
  mRs 0                1175             19.1                19.4                         302   15     18.6                  
  mRs 1                175              18.8                20.3   −3.63--3.01   0.856   31    20     19.4   −1.72--13.7    0.128
  mRs 2                193              18.4                20.4   −3.63--2.65   0.760   42    16.7   17.4   −3.74--7.69    0.498
  mRs 3                264              16                  15.3   −5.12--−0.5   0.014   48    16.8   17.5   −3.90--6.86    0.590
  mRs 4 or 5           262              14.9                15.3   −6.15--−0.6   0.015   25    12.4   13.3   −7.37--5.41    0.763
  **Comorbidity**                                                                                                           
  AF No                1965             17.5                18                           514   15.3   17.9                  
  AF Yes               474              18.2                19.4   −1.55--3.14   0.506   12    10.2   12.9   −9.62--9.56    0.996
  CHF No               2155             17.5                17.7                         520   15.3   17.9                  
  CHF Yes              284              18.7                22.5   −1.53--4.39   0.345   6     5.8    5.6    −18.4--−1.09   0.027
  CKD No               2385             17.6                18.3                         526   15.2   17.8                  
  CKD Yes              54               17                  17.1   −4.73--5.56   0.875   0     \-     \-                    
  MI No                2312             17.5                17.9                         503   15     17.4                  
  MI Yes               127              19.2                24.3   −3.78--6.08   0.647   23    18     25.4   −7.29--14.5    0.518
  DM No                2352             17.7                18.4                         525   15.2   17.8                  
  DM Yes               87               16.4                15.4   −2.49--5.17   0.492   1     1      \-                    
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###### 

Adjusted length of stay analysis with 95% confidence intervals of ischaemic and haemorrhagic TACS in patients who were alive at discharge.

                       Ischaemic TACS   Haemorrhagic TACS                                                                   
  -------------------- ---------------- ------------------- ------ -------------- ------- ----- ------ ------ ------------- -------
  **Age**                                                                                                                   
  \<65 years           119              25.1                25.5                          40    19.6   20.4                 
  65--84 years         669              24.4                19.7   −6.71--3.64    0.561   129   24.1   21.7   −5.37--9.76   0.569
  ≥85 years            272              25.2                20.7   −6.75--5.37    0.823   29    33.3   25.1   5.15--30.5    0.006
  **Gender**                                                                                                                
  Female               612              24.9                21                            102   25.4   22.7                 
  Male                 448              24.3                20.2   −3.41--2.36    0.720   96    23.6   21.8   −5.21--8.87   0.611
  **Lateralisation**                                                                                                        
  No                   59               29.3                29.1                          23    19.9   30.8                 
  Yes                  1001             24.4                20.1   −16.2--0.84    0.077   175   25.2   20.9   −7.79--22.2   0.346
  **Residence**                                                                                                             
  Home Alone           346              26.6                23.3                          66    26.6   24.8                 
  Home Family          591              24.4                19.8   −6.08--0.82    0.135   114   23.4   20.1   −11.6--4.50   0.387
  Care home            123              20.4                15.8   −12.2--−1.43   0.013   18    24.5   25.6   −20.4--10.1   0.506
  **Rankin Score**                                                                                                          
  mRs 0                625              25                  21.7                          125   24.4   23.3                 
  mRs 1                73               25.3                24.5   −5.70--5.99    0.962   10    30.1   22.2   −7.54--22.2   0.334
  mRs 2                79               24.1                16.1   −5.10--3.30    0.674   17    17     14.8   −18.8--2.88   0.150
  mRs 3                90               24.6                18.2   −4.59--4.43    0.973   14    30.6   24.7   −10.4--17.6   0.612
  mRs 4 or 5           79               21.4                17.8   −7.13--4.89    0.715   6     22.3   21.8   −18.5--9.01   0.499
  **Comorbidity**                                                                                                           
  AF No                902              24.3                20.5                          196   24.6   22.3                 
  AF Yes               158              27                  21.5   −3.52--4.88    0.750   2     17.5   17.7                 
  CHF No               979              24.1                20.2                          197   24.6   22.3                 
  CHF Yes              81               31.8                25     −0.11--11.1    0.055   1     16     \-                   
  CKD No               1043             24.6                20.7                          198   24.6   22.2                 
  CKD Yes              17               32.1                21.5   −1.85--17.2    0.114   0     NA     NA                   
  MI No                1017             24.3                20.5                          193   24     21.4                 
  MI Yes               43               32.4                22.6   −0.88--14.3    0.083   5     45.2   43.3                 
  DM No                1033             24.8                20.7                          198   24.6   22.2                 
  DM Yes               27               21                  19.1   −10.6--7.29    0.720   0     NA     NA                   
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###### 

Adjusted length of stay analysis with 95% confidence intervals of ischaemic and haemorrhagic TACS in patients who died during admission.

                       Ischaemic TACS   Haemorrhagic TACS                                                                  
  -------------------- ---------------- ------------------- ------ ------------- ------- ----- ------ ------ ------------- -------
  **Age**                                                                                                                  
  \<65 years           48               6.2                 7.4                          25    4.5    6.2                  
  65--84 years         712              11.7                12.8   2.82--8.59    0.000   207   9.4    10.8   −0.27--7.60   0.068
  ≥85 years            619              13.3                15.4   3.79--10.6    0.000   96    11     12.8   0.23--10.3    0.040
  **Gender**                                                                                                               
  Female               840              12.4                13.8                         165   8.9    8.9                  
  Male                 539              12                  14.3   −1.56--2.11   0.768   163   10.1   13.2   −0.32--5.20   0.084
  **Lateralisation**                                                                                                       
  No                   124              8.5                 10.8                         66    6.2    9.2                  
  Yes                  1255             12.6                14.2   1.28--6.18    0.003   262   10.3   11.6   0.80--6.93    0.014
  **Residence**                                                                                                            
  Home Alone           483              12.7                14.6                         93    8.8    8.2                  
  Home Family          620              11.6                13.8   −2.69--1.26   0.477   196   10     12.9   −1.60--4.67   0.337
  Care home            254              13                  12.8   −2.26--3.16   0.744   39    8.3    8      −7.65--2.36   0.300
  **Rankin Score**                                                                                                         
  mRs 0                550              12.3                13.5                         177   8.4    10.1                 
  mRs 1                102              14.2                15.2   −2.02--4.60   0.445   21    15.1   16.4   0.28--14.5    0.042
  mRs 2                114              14.5                22.1   −2.66--5.34   0.512   25    16.5   19.3   1.05--15.7    0.025
  mRs 3                174              11.5                11.3   −4.01--0.48   0.123   34    11     8.9    −0.55--6.83   0.095
  mRs 4 or 5           183              12.1                13.2   −4.39--1.07   0.233   19    9.3    7.9    −1.68--7.65   0.209
  **Comorbidity**                                                                                                          
  AF No                1063             11.7                13.1                         318   9.5    11.2                 
  AF Yes               316              13.7                16.7   −1.19--3.87   0.298   10    8.7    12.5   −8.71--13.1   0.693
  CHF No               1176             12                  12.9                         323   9.6    11.3                 
  CHF Yes              203              13.5                19.1   −1.61--4.60   0.344   5     3.8    2.8                  
  CKD No               1342             12.3                14.1                         328   9.5    11.2                 
  CKD Yes              37               10.1                8.3    −7.08--0.12   0.058   0     NA     NA                   
  MI No                1295             12.2                13.3                         310   9.4    11.3                 
  MI Yes               84               12.4                22.4   −6.24--5.32   0.877   18    10.4   10.7   −4.80--5.78   0.855
  DM No                1319             12.1                14                           327   9.5    11.2                 
  DM Yes               60               14.3                13.1   −1.55--6.27   0.237   1     1      NA                   
